$CGEN SEC Filings

Filed On	Filing
10 Sep 2026	6-K
04 Aug 2026	UPLOAD
03 Aug 2026	6-K
03 Aug 2026	6-K
30 Jul 2026	Form 4: Levine Zurit, SVP, Business Development Received 18,000 shares as a grant or award · Granted 24,000 Share Option (right to buy)
30 Jul 2026	Form 4: Silberman David, Chief Financial Officer Received 19,500 shares as a grant or award · Granted 26,000 Share Option (right to buy)
30 Jul 2026	Form 4: Ophir Eran, Director Granted 200,000 Share Option (right to buy)
30 Jul 2026	Form 4: Cohen-Dayag Anat, Director Granted 100,000 Share Option (right to buy)
30 Jul 2026	Form 4: Perry Eran, Director Received 7,500 shares as a grant or award · Granted 10,000 Share Option (right to buy)
30 Jul 2026	Form 4: Ferre Pierre, Chief Operating Officer Granted 70,000 Share Option (right to buy)
30 Jul 2026	Form 4: Kredo Russo Sharon, SVP, Research & Discovery Received 18,000 shares as a grant or award · Granted 24,000 Share Option (right to buy)
30 Jul 2026	Form 4: Livnat Savitzky Kinneret, Director Received 7,500 shares as a grant or award · Granted 10,000 Share Option (right to buy)
30 Jul 2026	Form 4: Hukkelhoven Mathias, Director Received 7,500 shares as a grant or award · Granted 10,000 Share Option (right to buy)
30 Jul 2026	Form 4: Halevy Gilead, Director Received 7,500 shares as a grant or award · Granted 10,000 Share Option (right to buy)
30 Jul 2026	Form 4: Zweifach Sanford S, Director Received 7,500 shares as a grant or award · Granted 10,000 Share Option (right to buy)
30 Jul 2026	Form 4: Mahler Michelle, Chief Medical Officer Received 13,500 shares as a grant or award · Granted 18,000 Share Option (right to buy)
28 Jul 2026	CORRESP
17 Jul 2026	UPLOAD
13 Jul 2026	Form 4: Levine Zurit, SVP, Business Development Received 1,875 shares by exercise or conversion ($1.55K) · Sold 1,875 shares ($4.69K)
08 Jun 2026	EFFECT

Comments